FI922770A0 - Bcrf1-proteinerna som inhibitorer av y-interferon. - Google Patents

Bcrf1-proteinerna som inhibitorer av y-interferon.

Info

Publication number
FI922770A0
FI922770A0 FI922770A FI922770A FI922770A0 FI 922770 A0 FI922770 A0 FI 922770A0 FI 922770 A FI922770 A FI 922770A FI 922770 A FI922770 A FI 922770A FI 922770 A0 FI922770 A0 FI 922770A0
Authority
FI
Finland
Prior art keywords
bcrf1
proteinerna
inhibitorer
som
interferon
Prior art date
Application number
FI922770A
Other languages
English (en)
Other versions
FI104883B (fi
FI922770A (fi
Inventor
Kevin W Moore
Robert A Kastelein
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of FI922770A0 publication Critical patent/FI922770A0/fi
Publication of FI922770A publication Critical patent/FI922770A/fi
Application granted granted Critical
Publication of FI104883B publication Critical patent/FI104883B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI922770A 1989-12-20 1992-06-16 Menetelmä valmistaa Epstein-Barr-viruksen BCRF1-proteiinia ja rekombinantti-ekspressiovektori FI104883B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45393189A 1989-12-20 1989-12-20
US45393189 1989-12-20
PCT/US1990/007288 WO1991009127A1 (en) 1989-12-20 1990-12-18 BCRF1 PROTEINS AS INHIBITORS OF INTERFERON-$g(g)
US9007288 1990-12-18

Publications (3)

Publication Number Publication Date
FI922770A0 true FI922770A0 (fi) 1992-06-16
FI922770A FI922770A (fi) 1992-06-16
FI104883B FI104883B (fi) 2000-04-28

Family

ID=23802631

Family Applications (1)

Application Number Title Priority Date Filing Date
FI922770A FI104883B (fi) 1989-12-20 1992-06-16 Menetelmä valmistaa Epstein-Barr-viruksen BCRF1-proteiinia ja rekombinantti-ekspressiovektori

Country Status (27)

Country Link
US (2) US5627155A (fi)
EP (1) EP0506836B1 (fi)
JP (1) JP2648236B2 (fi)
KR (1) KR960015199B1 (fi)
CN (1) CN1057012C (fi)
AT (1) ATE112317T1 (fi)
AU (1) AU7899694A (fi)
CA (1) CA2071907C (fi)
CZ (1) CZ283049B6 (fi)
DE (1) DE69013011T2 (fi)
DK (1) DK0506836T3 (fi)
ES (1) ES2064082T3 (fi)
FI (1) FI104883B (fi)
HK (1) HK185396A (fi)
HU (1) HU215909B (fi)
IE (1) IE72203B1 (fi)
IL (1) IL96715A0 (fi)
MX (1) MX9203409A (fi)
MY (1) MY107449A (fi)
NO (1) NO305703B1 (fi)
NZ (1) NZ236512A (fi)
OA (1) OA09703A (fi)
PH (1) PH31669A (fi)
PT (1) PT96231B (fi)
SK (1) SK279830B6 (fi)
WO (1) WO1991009127A1 (fi)
ZA (1) ZA9010188B (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
US5632988A (en) * 1989-10-23 1997-05-27 Schering Corporation Polypeptide inhibitors of gamma interferon
CZ282523B6 (cs) * 1991-01-16 1997-07-16 Schering Corporation Iterleukin - 10 pro léčení nádorů, farmaceutický prostředek jej obsahující, jeho použití a způsob výroby
US6106823A (en) 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
EP0600970B1 (en) * 1991-08-06 1999-12-08 Schering Corporation Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
DE69334191T2 (de) * 1992-03-13 2008-11-27 bioMérieux B.V. Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmente
US6008327A (en) * 1992-03-13 1999-12-28 Akzo Nobel, N.V. Peptides and nucleic acid sequences related to the Epstein Barr virus
WO1993018783A1 (en) * 1992-03-20 1993-09-30 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
EP0726315B1 (en) * 1993-07-23 2001-10-17 Hans Prof. Dr. Wolf Epstein-Barr virus DNA sequences encoding a diagnostically relevant virus capsid antigen, expression clones derived through polymerase chain reaction and the use of this recombinant antigen in diagnostic tests
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
DE69840216D1 (de) * 1997-08-08 2008-12-24 Celmed Oncology Usa Inc Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden
JP2015505300A (ja) 2011-11-23 2015-02-19 アムジエン・インコーポレーテツド インターフェロンγに対する抗体を使用した治療方法
WO2022016509A1 (zh) * 2020-07-24 2022-01-27 阎忠扬 一种用以筛选药物的方法，以及该药物用于治疗牛皮癣的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583564D1 (de) * 1984-08-23 1991-08-29 Hans Joachim Wolf Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
US5256768A (en) * 1985-12-13 1993-10-26 The Johns Hopkins University Expression of antigenic Epstein-Barr virus polypeptides in bacteria and their use in diagnostics

Also Published As

Publication number Publication date
JP2648236B2 (ja) 1997-08-27
ES2064082T3 (es) 1995-01-16
SK635190A3 (en) 1999-04-13
ATE112317T1 (de) 1994-10-15
MY107449A (en) 1995-12-31
ZA9010188B (en) 1991-08-28
PH31669A (en) 1999-01-18
US5627155A (en) 1997-05-06
MX9203409A (es) 1992-07-01
NO305703B1 (no) 1999-07-12
KR960015199B1 (ko) 1996-11-01
EP0506836A1 (en) 1992-10-07
NZ236512A (en) 1997-07-27
HU9202075D0 (en) 1992-10-28
DK0506836T3 (da) 1994-11-28
IE72203B1 (en) 1997-04-09
AU652732B2 (en) 1994-09-08
AU7899694A (en) 1995-02-09
WO1991009127A1 (en) 1991-06-27
DE69013011T2 (de) 1995-02-23
IE904588A1 (en) 1991-07-03
JPH05503846A (ja) 1993-06-24
CN1057012C (zh) 2000-10-04
HK185396A (en) 1996-10-11
OA09703A (en) 1993-08-30
DE69013011D1 (de) 1994-11-03
PT96231A (pt) 1991-09-30
PT96231B (pt) 1998-09-30
HUT65369A (en) 1994-05-02
EP0506836B1 (en) 1994-09-28
AU7063691A (en) 1991-07-18
IL96715A0 (en) 1991-09-16
CA2071907A1 (en) 1991-06-21
CZ635190A3 (en) 1997-09-17
SK279830B6 (sk) 1999-04-13
CN1052608A (zh) 1991-07-03
CZ283049B6 (cs) 1997-12-17
HU215909B (hu) 1999-03-29
US5736390A (en) 1998-04-07
FI104883B (fi) 2000-04-28
NO922456D0 (no) 1992-06-19
FI922770A (fi) 1992-06-16
NO922456L (no) 1992-06-19
CA2071907C (en) 2000-08-08

Similar Documents

Publication Publication Date Title
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
FI922770A (fi) Bcrf1-proteinerna som inhibitorer av y-interferon.
ES8602768A1 (es) Un procedimiento para la preparacion de nuevas n-(heterociclil biciclo)-4-piperidinaminas.
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
DE3877529D1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.
ATE165010T1 (de) Menschliches ifn-beta2/il-6, dessen reinigung und verwendungen
DE3688038D1 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
DE69130679D1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
MX9202366A (es) Nuevas 2-amino-5-ciano-1,4-di hidro piridinas y procedimiento para su fabricacion.
ES2076141T3 (es) 5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
ATE168698T1 (de) Zubereitungen zur verwendung bei der behandlung von psoriasis und von neuropsychiatrischen krankheiten
ES2166800T3 (es) Procedimiento para la preparacion de o,s-acetales de 2,2-difluoroceteno sililo y o,s-esteres del acido alfa,alfa-difluoro-beta-sililoxi-1,3-dioxolan-4-propanoico.
DE3764559D1 (de) 4-benzyloxy-3-pyrrolin-2-on-1-yl-acetamid, dessen herstellung und verwendung.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
FI944907A0 (fi) Uusi antineoplastinen sytokiini
DE69011565D1 (de) Herstellung von Pre-Kaseinaten und Verwendung.
ATE84543T1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.